Claims
- 1. A method of treatment of a behavioral disorder selected from aggressive disorder, obsessive-compulsive disorder, anxiety, depression, or ADHD in a patient in need of such treatment, said method comprising the step of administering to said patient an effective amount of a compound capable of inhibiting the activity of a carboxypeptidase E in the brain of said patient.
- 2. The method of claim 1 wherein the behavioral disorder is depression or obsessive-compulsive disorder.
- 3. The method of claim 1 wherein the peptidase inhibitor is administered as an antiaggressive agent to control impulsivity and violence in a human patient afflicted with autism, Tourette's syndrome, mental retardation, psychosis, mania, senile dementia or in a patient with a personality disorder and history of inappropriate aggression.
- 4. The method of claim 1 wherein the compound is administered to a human patient suffering a behavioral disorder comprising anxiety.
- 5. The method of claim 1 wherein the compound is administered to a human patient suffering a behavioral disorder comprising ADHD.
- 6. The method of claim 1 wherein the peptidase inhibitor is a moxalactam or a pharmaceutically acceptable salt or ester thereof.
- 7. The method of claim 6 wherein the behavioral disorder is depression or obsessive-compulsive disorder.
- 8. The method of claim 6 wherein the peptidase inhibitor is administered as an antiaggressive agent to control impulsivity and violence in a human patient afflicted with autism, Tourette's syndrome, mental retardation, psychosis, mania, senile dementia or in a patient with a personality disorder and history of inappropriate aggression.
- 9. The method of claim 6 wherein the compound is administered to a human patient suffering a behavioral disorder comprising anxiety.
- 10. The method of claim 6 wherein the compound is administered to a human patient suffering a behavioral disorder comprising ADHD.
- 11. The method of claim 1 wherein the peptidase inhibitor is a flomoxef or a pharmaceutically acceptable salt or ester thereof.
- 12. The method of claim 11 wherein the behavioral disorder is depression or obsessive-compulsive disorder.
- 13. The method of claim 11 wherein the peptidase inhibitor is administered as an antiaggressive agent to control impulsivity and violence in a human patient afflicted with autism, Tourette's syndrome, mental retardation, psychosis, mania, senile dementia or in a patient with a personality disorder and history of inappropriate aggression.
- 14. The method of claim 11 wherein the compound is administered to a human patient suffering a behavioral disorder comprising anxiety.
- 15. The method of claim 11 wherein the compound is administered to a human patient suffering a behavioral disorder comprising ADHD.
- 16. The method of claim 1 wherein the peptidase inhibitor is a compound of the formula
- 17. A method of enhancing cognitive function in a patient in need of said treatment, said method comprising the step of administering to said patient an effective amount of a compound capable of inhibiting the peptidase activity of carboxypeptidase E in the brain of said patient.
- 18. The method of claim 17 wherein the warm-blooded vertebrate is a human patient suffering from dementia or amnesia.
- 19. The method of claim 17 wherein the warm-blooded vertebrate is a human patient suffering from Alzheimer's Disease.
- 20. The method of claim 17 wherein the peptidase inhibitor is a moxalactam or a pharmaceutically acceptable salt or ester thereof.
- 21. The method of claim 17 wherein the peptidase inhibitor is a flomoxef or a pharmaceutically acceptable salt or ester thereof.
- 22. The method of claim 17 wherein the peptidase inhibitor is a compound of the formula
- 23. A method for treatment of anxiety disorders in a human patient in need of said treatment, said method comprising the step of administering an inhibitor of a neurogenic peptidase to said patient in an amount effective to modulate carboxy peptidase E activity in the brain of said patient.
- 24. The method of claim 23 wherein the peptidase inhibitor is a moxalactam or a pharmaceutically acceptable salt or ester thereof.
- 25. The method of claim 23 wherein the peptidase inhibitor is a flomoxef or a pharmaceutically acceptable salt or ester thereof.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. Ser. No. 09/640,363, filed Aug. 16, 2000, which claims priority to U.S. Provisional Applications Ser. Nos. 60/149,115, filed Aug. 16, 1999; 60/172,452, filed Dec. 17, 1999; 60/176,570, filed Jan. 18, 2000; and 60/194,534, filed Apr. 4, 2000.
Provisional Applications (4)
|
Number |
Date |
Country |
|
60149115 |
Aug 1999 |
US |
|
60172452 |
Dec 1999 |
US |
|
60176570 |
Jan 2000 |
US |
|
60194534 |
Apr 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09640363 |
Aug 2000 |
US |
Child |
09783201 |
Feb 2001 |
US |